Cargando…

Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy

Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic he...

Descripción completa

Detalles Bibliográficos
Autores principales: González, Fermín E., Chernobrovkin, Alexey, Pereda, Cristián, García-Salum, Tamara, Tittarelli, Andrés, López, Mercedes N., Salazar-Onfray, Flavio, Zubarev, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878886/
https://www.ncbi.nlm.nih.gov/pubmed/29744371
http://dx.doi.org/10.1155/2018/3982942
_version_ 1783310909656006656
author González, Fermín E.
Chernobrovkin, Alexey
Pereda, Cristián
García-Salum, Tamara
Tittarelli, Andrés
López, Mercedes N.
Salazar-Onfray, Flavio
Zubarev, Roman A.
author_facet González, Fermín E.
Chernobrovkin, Alexey
Pereda, Cristián
García-Salum, Tamara
Tittarelli, Andrés
López, Mercedes N.
Salazar-Onfray, Flavio
Zubarev, Roman A.
author_sort González, Fermín E.
collection PubMed
description Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival. TRIMEL provides not only a broad spectrum of potential melanoma-associated antigens but also danger signals that are crucial in the induction of a committed mature DC phenotype. However, potential changes induced by heat conditioning on the proteome of TRIMEL are still unknown. The identification of newly or differentially expressed proteins under defined stress conditions is relevant for understanding the lysate immunogenicity. Here, we characterized the proteomic profile of TRIMEL in response to HS treatment. A quantitative label-free proteome analysis of over 2800 proteins was performed, with 91 proteins that were found to be regulated by HS treatment: 18 proteins were overexpressed and 73 underexpressed. Additionally, 32 proteins were only identified in the HS-treated TRIMEL and 26 in non HS-conditioned samples. One protein from the overexpressed group and two proteins from the HS-exclusive group were previously described as potential damage-associated molecular patterns (DAMPs). Some of the HS-induced proteins, such as haptoglobin, could be also considered as DAMPs and candidates for further immunological analysis in the establishment of new putative danger signals with immunostimulatory functions.
format Online
Article
Text
id pubmed-5878886
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58788862018-05-09 Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy González, Fermín E. Chernobrovkin, Alexey Pereda, Cristián García-Salum, Tamara Tittarelli, Andrés López, Mercedes N. Salazar-Onfray, Flavio Zubarev, Roman A. J Immunol Res Research Article Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival. TRIMEL provides not only a broad spectrum of potential melanoma-associated antigens but also danger signals that are crucial in the induction of a committed mature DC phenotype. However, potential changes induced by heat conditioning on the proteome of TRIMEL are still unknown. The identification of newly or differentially expressed proteins under defined stress conditions is relevant for understanding the lysate immunogenicity. Here, we characterized the proteomic profile of TRIMEL in response to HS treatment. A quantitative label-free proteome analysis of over 2800 proteins was performed, with 91 proteins that were found to be regulated by HS treatment: 18 proteins were overexpressed and 73 underexpressed. Additionally, 32 proteins were only identified in the HS-treated TRIMEL and 26 in non HS-conditioned samples. One protein from the overexpressed group and two proteins from the HS-exclusive group were previously described as potential damage-associated molecular patterns (DAMPs). Some of the HS-induced proteins, such as haptoglobin, could be also considered as DAMPs and candidates for further immunological analysis in the establishment of new putative danger signals with immunostimulatory functions. Hindawi 2018-03-18 /pmc/articles/PMC5878886/ /pubmed/29744371 http://dx.doi.org/10.1155/2018/3982942 Text en Copyright © 2018 Fermín E. González et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
González, Fermín E.
Chernobrovkin, Alexey
Pereda, Cristián
García-Salum, Tamara
Tittarelli, Andrés
López, Mercedes N.
Salazar-Onfray, Flavio
Zubarev, Roman A.
Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
title Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
title_full Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
title_fullStr Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
title_full_unstemmed Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
title_short Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
title_sort proteomic identification of heat shock-induced danger signals in a melanoma cell lysate used in dendritic cell-based cancer immunotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878886/
https://www.ncbi.nlm.nih.gov/pubmed/29744371
http://dx.doi.org/10.1155/2018/3982942
work_keys_str_mv AT gonzalezfermine proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT chernobrovkinalexey proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT peredacristian proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT garciasalumtamara proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT tittarelliandres proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT lopezmercedesn proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT salazaronfrayflavio proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy
AT zubarevromana proteomicidentificationofheatshockinduceddangersignalsinamelanomacelllysateusedindendriticcellbasedcancerimmunotherapy